LOGIN  |  REGISTER
Cue Biopharma

Zynex Included in Denver-Area's Top 10 Biotechnology/Bioscience Companies

March 21, 2023 | Last Trade: US$8.20 0.02 -0.24

ENGLEWOOD, Colo., March 21, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Denver Business Journal has ranked Zynex sixth in a list of the largest Denver-area Biotechnology/Bioscience companies, according to the number of full-time employees (FTEs).

"Zynex has experienced significant revenue and order growth over the last several years, and we have invested heavily in the expansion of our quality workforce" said Thomas Sandgaard, CEO and founder of Zynex Inc. "We remain committed to being a high-quality workplace and industry leader in the Denver-area."

About Denver Business Journal

American City Business Journals (ACBJ) is the largest publisher of metropolitan business newsweeklies in the United States, with 44 business publications across the country reaching more than 3.6 million readers each week.

About Zynex, Inc. 

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com 

Contact: Zynex, Inc. (800) 495-6670

Investor Relations Contact:
Gilmartin Group
Investor Relations Counsel
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB